OverviewSuggest Edit

Translate Bio develops medicines to treat diseases caused by protein or gene dysfunction. It uses single-stranded oligonucleotides to target the repressive interactions of long non-coding RNA (lncRNA) with specific genes of interest, thereby upregulating mRNA and increasing expression of the encoded protein. The Company is applying its proprietary technology to develop new treatments in several therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, oncology, metabolic diseases and neurodegenerative diseases.
TypePublic
Founded2011
HQLexington, MA, US
Websitetranslate.bio
Employee Ratings4.3

Latest Updates

Employees (est.) (Dec 2018)81(+33%)
Job Openings10
Revenue (FY, 2020)$138.8 M(+1679%)
Share Price (Sept 2021)$37.4
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Translate Bio

Ronald C. Renaud

Ronald C. Renaud

CEO & Director
Rand Sutherland

Rand Sutherland

President
Ann Barbier

Ann Barbier

Chief Medical Officer
Paul Burgess

Paul Burgess

Chief Legal Officer and Chief Operating Officer
Brian Fenton

Brian Fenton

Chief Business Officer
Paula Cloghessy

Paula Cloghessy

Chief People Officer
Show more

Translate Bio Office Locations

Translate Bio has an office in Lexington
Lexington, MA, US (HQ)
29 Hartwell Ave
Show all (1)

Translate Bio Financials and Metrics

Translate Bio Revenue

Translate Bio's revenue was reported to be $138.81 m in FY, 2020
USD

Revenue (Q1, 2021)

34.6m

Net income (Q1, 2021)

26.5m

EBIT (Q1, 2021)

26.6m

Market capitalization (17-Sept-2021)

2.8b

Closing stock price (17-Sept-2021)

37.4

Cash (31-Mar-2021)

155.7m

EV

2.7b
Translate Bio's current market capitalization is $2.8 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.4m7.8m138.8m

General and administrative expense

11.1m14.3m22.6m28.6m35.9m

R&D expense

15.7m47.0m58.0m76.4m109.6m

Operating expense total

26.8m79.2m80.6m105.0m145.6m
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

238.0k1.5m1.2m1.3m4.7m16.3m66.4m34.6m

General and administrative expense

3.0m4.8m6.0m6.0m6.6m7.9m6.9m7.5m8.6m9.2m10.8m

R&D expense

9.6m12.7m15.2m12.9m17.4m16.6m17.3m21.4m29.0m26.3m41.1m

Operating expense total

14.9m22.4m21.2m18.9m24.0m24.5m24.2m28.9m37.6m35.5m52.0m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

57.7m48.1m55.2m84.6m342.0m

Prepaid Expenses

685.0k3.0m4.5m9.4m11.7m

Current Assets

205.6m198.5m149.6m203.6m697.2m

PP&E

4.9m6.8m10.2m12.5m15.4m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

30.8m16.5m38.9m62.4m74.9m98.9m97.5m272.2m674.1m155.7m

Prepaid Expenses

4.3m4.8m4.2m5.2m6.1m6.6m6.9m7.9m10.8m16.7m

Current Assets

182.8m24.3m166.3m128.9m153.9m217.8m169.2m316.2m711.0m699.5m

PP&E

9.2m9.9m10.1m10.8m10.9m10.7m13.8m15.2m15.0m16.6m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(26.7m)(66.4m)(97.4m)(113.3m)

Depreciation and Amortization

730.0k1.6m2.8m4.7m9.3m

Accounts Payable

84.0k4.0m658.0k9.9m(6.6m)

Cash From Operating Activities

(23.7m)(50.8m)(22.1m)(82.2m)236.3m
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(14.0m)(21.2m)(48.7m)(91.4m)(33.2m)(61.0m)(82.3m)(14.3m)(33.2m)26.5m

Depreciation and Amortization

191.0k536.0k1.4m1.9m1.0m2.0m3.0m1.4m5.6m6.4m2.8m

Accounts Payable

698.0k1.5m1.1m(1.6m)(1.0m)(1.9m)(1.7m)(9.5m)(2.8m)(8.6m)8.1m

Cash From Operating Activities

(9.6m)(16.9m)(33.6m)(5.9m)(21.5m)(41.4m)(61.9m)(31.4m)(51.5m)258.3m689.0k
USDFY, 2016

Financial Leverage

-5.3 x
Show all financial metrics

Translate Bio Acquisitions / Subsidiaries

Company NameDateDeal Size
Translate Bio MA
Translate Bio Securities Corporation

Translate Bio Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Translate Bio Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Translate Bio Online and Social Media Presence

Embed Graph

Translate Bio News and Updates

Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update

-- Entered into a definitive agreement under which Sanofi will acquire, subject to customary conditions to closing, all outstanding shares of Translate Bio with a goal of advancing deployment of mRNA technology across vaccines and therapeutics development -- -- Advanced mRNA infectious disease vacci…

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Translate Bio, Inc. Merger

WILMINGTON, Del., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Translate Bio, Inc. (“Translate Bio”) (NASDAQ GS: TBIO) regarding possible breaches of fiduciary duties and other violations of law related to Translate Bio’s agreement to be acquired by Sano…

Translate Bio soars 30% after Sanofi agrees to buy the mRNA company for $3.2 billion (TBIO)

Summary List Placement Shares of Translate Bio surged 30% on Tuesday after Sanofi agreed to buy the mRNA developer for $3.2 billion. Sanofi will purchase Translate Bio for $38 per share in cash and fast track its mRNA technology. The move comes following the success of Moderna, which developed a m…

Sanofi Buys U.S. Partner Translate Bio For $3.2 Billion As Pharma Giant Bets Big On mRNA Tech

Pfizer, BioNTech and Moderna used mRNA to build effective Covid-19 vaccines in record time, a feat Sanofi is keen to build upon in the future.
Show more

Translate Bio Frequently Asked Questions

  • When was Translate Bio founded?

    Translate Bio was founded in 2011.

  • Who are Translate Bio key executives?

    Translate Bio's key executives are Ronald C. Renaud, Rand Sutherland and Ann Barbier.

  • How many employees does Translate Bio have?

    Translate Bio has 81 employees.

  • What is Translate Bio revenue?

    Latest Translate Bio annual revenue is $138.8 m.

  • What is Translate Bio revenue per employee?

    Latest Translate Bio revenue per employee is $1.7 m.

  • Who are Translate Bio competitors?

    Competitors of Translate Bio include Truvian Sciences, Biosynex and HeMemics Biotechnologies.

  • Where is Translate Bio headquarters?

    Translate Bio headquarters is located at 29 Hartwell Ave, Lexington.

  • Where are Translate Bio offices?

    Translate Bio has an office in Lexington.

  • How many offices does Translate Bio have?

    Translate Bio has 1 office.